跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
2-Hydroxyethyl Disulfide
首页
药物
2-Hydroxyethyl Disulfide
Experimental
Small Molecule
2-Hydroxyethyl Disulfide
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
技术标识符
化学式
C
4
H
10
O
2
S
2
CAS 编号
1892-29-1
UNII ID
45543L74BS
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
Preparation process of biapenem
CN 103570750 A
申请人: ANHUI YOUCARE KAIYUE PHARMACEUTICAL CO LTD
优先权: 2013
CN
Amphiphilic block copolymer containing disulfide bonds as well as preparation method and application of amphiphilic block copolymer
CN 110218291 A
申请人: UNIV XIANGTAN
优先权: 2019
CN
Amphiphilic copolymer as well as preparation and application of nano micelle system of copolymer
CN 110183613 A
申请人: UNIV XIANGTAN
优先权: 2019
CN
Reduction responsive cross-linking agent and preparation and application of cross-linked hydroxyl drug molecules of reduction responsive cross-linking agent
CN 111053911 A
申请人: UNIV SOUTHWEST
优先权: 2019
CN
Synthesis method and application of mitochondrial targeting and responding porphyrinyl supramolecular self-assembled nano system
CN 119424636 A
申请人: UNIV HENAN NORMAL
优先权: 2024
CN
Preparation method of nano-micelle for reducing responsive sensitization tumor immunochemotherapy
CN 120053368 A
申请人: UNIV ZHENGZHOU
优先权: 2025
CN
Preparation method of carrier-free nano-drug delivery system CSCN and application of carrier-free nano-drug delivery system CSCN in breast cancer treatment
CN 120392669 A
申请人: UNIV NANJING NORMAL
优先权: 2025
CN
Medicine for treating sepsis-related encephalopathy and preparation method thereof
CN 120585752 A
申请人: THE SECOND HOSPITAL OF DALIAN MEDICAL UNIV
优先权: 2025
CN
Ferroptosis prodrug compound targeting mitochondrial autophagy as well as preparation method and application of ferroptosis prodrug compound
CN 120904244 A
申请人: UNIV JIANGXI NORMAL
优先权: 2025
CN
Reduction-sensitive transferrin functionalized prodrug nanocomposite as well as construction method and application thereof
CN 121313856 A
申请人: UNIV SHENYANG PHARMACEUTICAL
优先权: 2025
CN
药物
反馈